State of Alaska Department of Revenue Sells 6,285 Shares of Gilead Sciences, Inc. $GILD

Key Points

• The State of Alaska Department of Revenue reduced its holdings in Gilead Sciences by 3.4%, selling 6,285 shares in the second quarter, leaving them with a total of 178,037 shares valued at approximately $19.7 million.
• Insider Johanna Mercier sold 28,000 shares at an average price of $118.53, decreasing her ownership by 19.7%, while total insider sales in the last ninety days reached 82,000 shares valued at over $9.3 million.
• Gilead Sciences reported $2.01 EPS in their latest earnings announcement, beating estimates and showing a revenue increase of 1.4% year-over-year, with a set guidance of 7.950-8.250 EPS for FY 2025.

State of Alaska Department of Revenue lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 178,037 shares of the biopharmaceutical company's stock after selling 6,285 shares during the period. State of Alaska Department of Revenue's holdings in Gilead Sciences were worth $19,738,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the first quarter valued at about $25,000. Activest Wealth Management grew its holdings in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the first quarter valued at about $29,000. Colonial Trust Advisors grew its holdings in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital grew its holdings in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,390,030 in the last ninety days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $112.10 on Friday. The business has a 50-day moving average price of $114.41 and a 200-day moving average price of $109.95. Gilead Sciences, Inc. has a twelve month low of $82.82 and a twelve month high of $121.83. The firm has a market cap of $139.09 billion, a price-to-earnings ratio of 22.33, a price-to-earnings-growth ratio of 0.75 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the company earned $2.01 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent research reports. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Finally, Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.